Organisation paid for research Program year 2025 Source: CMS Open Payments

Advanced Urology Institute

Neither a doctor nor a teaching hospital

Research payments

$619,670

141 payments

Through program year 2025, Advanced Urology Institute is reported as receiving $619,670 in research payments, across 141 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $72,025 18
2024 Research $271,787 32
2023 Research $109,730 17
2022 Research $19,267 12
2021 Research $21,107 13
2020 Research $60,131 23
2019 Research $65,624 26

Breakdown

Who paid Research payments · program years 2019–2025
  1. Janssen Research & Development, LLC $245,642 75 payments
  2. Sumitomo Pharma America, Inc. $244,931 23 payments
  3. Coloplast Corp $40,709 11 payments
  4. Dendreon Pharmaceuticals LLC $32,221 13 payments
  5. NeoTract Inc. $28,170 4 payments
  6. OPKO Pharmaceuticals, LLC $9,514 3 payments
  7. Astellas Pharma Global Development $9,278 8 payments
  8. SRS Medical Systems, Inc. $3,878 1 payment
  9. Urotronic, Inc $3,328 2 payments
  10. Cytyc Surgical Products, LLC $2,000 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. Relugolix Versus Leuprolide in Patients With Prostate Cancer: A Randomized, Open-Label Study to Assess Major Adverse Cardiovascular Events (Replace-Cv) $191,443 15 payments
  2. A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) $143,217 18 payments
  3. Relugolix Versus Leuprolide in Patients With Prostate Cancer: A Randomized, Open-Label Study to Assess Major Adverse Cardiovascular Events (Replace-Cv) $44,488 6 payments
  4. Intibia $40,709 11 payments
  5. Biomarker Study to Determine Frequency of DNA repair Defects in Men with Metastatic Prostate Cancer $36,830 5 payments
  6. A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer $36,772 18 payments
  7. Real World Study $28,170 4 payments
  8. Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer Provent $18,153 5 payments
  9. Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer (Provent) $9,950 4 payments
  10. Effects and Safety of OPK-88004 Doses in Men With Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) $9,514 3 payments
What the money was spent on Research payments · program years 2019–2025
  1. Other $3,878 1 payment
  2. Patient care $2,002 1 payment
  3. Overhead $2,002 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record